12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Nimbus Discovery preclinical data

In human peripheral blood mononuclear cells (PBMCs) and activated B cell-like DLBCL cell lines, ND-2158 suppressed secretion of IL-6 and IL-10. Furthermore, Nimbus said ND-2158 plus ibrutinib synergistically induced selective cell death in hematologic tumors with the activating

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >